These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 225280)

  • 1. Oxidation state of technetium in bone scanning agents as determined at carrier concentration by amperometric titration.
    Russell CD; Cash AG
    Int J Appl Radiat Isot; 1979 Aug; 30(8):485-8. PubMed ID: 225280
    [No Abstract]   [Full Text] [Related]  

  • 2. Valence state of technetium in technetium methylene diphosphonate at tracer concentrations, measured by amperometry.
    Mulder G; Oldenburg SJ; van Oort WJ; den Hartigh JD
    Int J Appl Radiat Isot; 1981 Sep; 32(9):675-7. PubMed ID: 6457808
    [No Abstract]   [Full Text] [Related]  

  • 3. What do we want from a bone-scanning agent?
    Fogelman I; Bessent RG
    J Nucl Med; 1980 Mar; 21(3):296. PubMed ID: 6445001
    [No Abstract]   [Full Text] [Related]  

  • 4. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate.
    Subramanian G; McAfee JG; Thomas FD; Feld TA; Zapf-Longo C; Palladino E
    Radiology; 1983 Dec; 149(3):823-8. PubMed ID: 6316414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bone scan as a tumour marker in prostatic carcinoma.
    Chisholm GD; Stone AR; Beynon LL; Merrick MV
    Eur Urol; 1982; 8(5):257-60. PubMed ID: 6288389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation absorbed dose from technetium-99m-labeled bone imaging agents. Task Group of the Medical Internal Radiation Dose Committee, The Society of Nuclear Medicine.
    Weber DA; Makler PT; Watson EE; Coffey JL; Thomas SR; London J
    J Nucl Med; 1989 Jun; 30(6):1117-22. PubMed ID: 2544697
    [No Abstract]   [Full Text] [Related]  

  • 7. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model.
    Bevan JA; Tofe AJ; Benedict JJ; Francis MD; Barnett BL
    J Nucl Med; 1980 Oct; 21(10):967-70. PubMed ID: 6252299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone scintigraphy with Tc-99m methylene diphosphonate: a comparison with ethane-hydroxy-diphosphonate (author's transl)].
    Nakano S; Hasegawa Y; Shiomura K; Ibuka K
    Kaku Igaku; 1978 Jun; 15(4):587-90. PubMed ID: 100638
    [No Abstract]   [Full Text] [Related]  

  • 9. New vistas on bone scintigraphy.
    Nucl Med Commun; 1984 Jun; 5(6):359-60. PubMed ID: 6241663
    [No Abstract]   [Full Text] [Related]  

  • 10. The clinical comparison of skeletal imaging agents.
    Adams FG; Horton PW; Stenhouse G
    Eur J Nucl Med; 1980 Jun; 5(3):257-60. PubMed ID: 6771137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. I. Synthesis and distribution in animals.
    Bevan JA; Tofe AJ; Benedict JJ; Francis MD; Barnett BL
    J Nucl Med; 1980 Oct; 21(10):961-6. PubMed ID: 6252298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the performance and interpretation of bone scans.
    Muroff LR
    Clin Nucl Med; 1981 Oct; 6(10S):P68-76. PubMed ID: 6271444
    [No Abstract]   [Full Text] [Related]  

  • 13. Labeling efficiency and stomach concentration in methylene diphosphonate bone imaging.
    Dhawan V; Yeh SD
    J Nucl Med; 1979 Jul; 20(7):791-3. PubMed ID: 541718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical studies on the detection of bone metastasis in lung cancer by bone scintigraphy].
    Nakano S; Hasegawa Y; Kajita A; Nakamura S; Horai T; Ikegami H; Matuda M; Okamoto N; Nabeshima H; Doi O; Komatubara Y; Ishigami S
    Kaku Igaku; 1983 Feb; 20(1):37-43. PubMed ID: 6308314
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of bone scintigraphy in differential diagnosis of benign bone tumors].
    Okuyama T; Suzuki H; Nakamoto K; Suzuki S
    Kaku Igaku; 1982 Dec; 19(10):1519-30. PubMed ID: 6302357
    [No Abstract]   [Full Text] [Related]  

  • 16. Diphosphonates in the evaluation of metabolic bone disease.
    Fogelman I; Smith ML
    Clin Rheumatol; 1982 Mar; 1(1):41-4. PubMed ID: 6236012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renal failure and metabolic diseases upon bone scanning in children.
    Schümichen C
    Ann Radiol (Paris); 1983; 26(6):498-504. PubMed ID: 6316830
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of acute administration of ethane hydroxydiphosphonate (EHDP) on skeletal scintigraphy with technetium-99m methylene diphosphonic acid (Tc-MDP) in the rat.
    Watt I; Hill P
    Br J Radiol; 1981 Jul; 54(643):592-6. PubMed ID: 6455174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone scintigraphy in evaluation of Didronel therapy for Paget's disease.
    Lee JY
    Clin Nucl Med; 1981 Aug; 6(8):356-8. PubMed ID: 6455232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of pre-treatment and follow-up skeletal scintigraphy in operable breast cancer.
    Pauwels EK; Heslinga JM; Zwaveling A
    Clin Oncol; 1982 Mar; 8(1):25-32. PubMed ID: 6280915
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.